Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Modulation of Attention Explored in ERPs as a Marker of Early Cognitive Decline: Concept Validation on the Effect of Ginkgo Biloba Extracts. Randomized, Double-blind, Cross-over, Placebo-controlled Study

NCT04121728 is registered in ClinicalTrials.gov with Jean-François Démonet as lead sponsor.

NCT NCT04121728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04121728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Modulation of Attention Explored in ERPs as a Marker of Early Cognitive Decline: Concept Validation on the Effect of Ginkgo Biloba Extracts. Randomized, Double-blind, Cross-over, Placebo-controlled Study
Lead sponsor
Jean-François Démonet
Phase
Not applicable
Overall status
Unknown status
Start date
September 9, 2019
Completion date
May 31, 2024
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related cognitive decline, cognitive performance, functional capacity, subjective cognitive decline